You are viewing: Asia Pacific Oral Proteins & Peptides Market analysis

The Asia Pacific Oral Proteins & Peptides Market was valued at $514.2 Million in 2025 and projected to reach to $1135 Million by 2030, representing a compound annual growth rate of 17.2%. Asia Pacific's oral proteins & peptides market is positioned for exceptional growth through 2030, driven by rising healthcare investments, expanding pharmaceutical manufacturing capabilities, and increasing patient awareness of advanced treatment options.

Asia Pacific Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Asia Pacific Oral Proteins & Peptides Market Trends and Insights

  • Asia Pacific's growth trajectory reflects rising demand for innovative drug delivery systems and increasing prevalence of chronic diseases across the region.
  • The 17.2% compound annual growth rate underscores Asia Pacific's position as a high-growth market, driven by expanding pharmaceutical R&D investments and improving healthcare infrastructure. Asia Pacific's oral proteins & peptides sector benefits from a large patient population, growing biopharmaceutical manufacturing capabilities, and regulatory advancements that facilitate market entry.
  • Between 2025 and 2030, Asia Pacific is expected to capture significant market share as companies invest in oral bioavailability technologies and peptide therapeutics.
  • The region's competitive landscape includes both multinational corporations and emerging local players leveraging Asia Pacific's cost advantages and manufacturing expertise..

Key Market Statistics

  • CAGR (2025-2030) 17.2% CAGR
  • Market Size, 2025 ~USD 514.2 Million
  • Forecast, 2030 ~USD 1135 Million
  • Geography Asia Pacific

Asia Pacific Oral Proteins & Peptides Market Overview

Strong Regional Growth Trajectory :

Asia Pacific's oral proteins & peptides market is expanding at 17.2% CAGR, significantly outpacing mature markets and reflecting the region's increasing adoption of advanced biopharmaceutical technologies and innovative delivery mechanisms.

Market Valuation Expansion :

The market is valued at $514.2 million in 2025 and is projected to more than double to $1,135.0 million by 2030, demonstrating substantial investment opportunities and growing healthcare expenditure across Asia Pacific economies.

Rising Chronic Disease Burden :

Increasing prevalence of diabetes, cardiovascular diseases, and gastrointestinal disorders across Asia Pacific is driving demand for oral protein and peptide-based therapeutics as preferred treatment modalities over traditional injectable alternatives.

Innovation in Drug Delivery Systems :

Asia Pacific markets are witnessing accelerated development of novel oral delivery technologies, including permeation enhancers and protective formulations, enabling better bioavailability and patient compliance for protein and peptide therapeutics.

Asia Pacific Oral Proteins & Peptides Market Dynamics

  • The region's growing middle-class population and improving healthcare infrastructure are creating substantial demand for innovative biopharmaceutical solutions.
  • Key markets including China, Japan, and India are investing heavily in biotechnology research and development, fostering an environment conducive to oral protein and peptide drug development and commercialization. Regulatory frameworks across Asia Pacific are evolving to support faster approval pathways for novel therapeutics, while partnerships between regional and global pharmaceutical companies are accelerating market penetration.
  • The convergence of rising chronic disease prevalence, technological advancement in oral delivery systems, and increased healthcare spending positions Asia Pacific as a critical growth engine for the global oral proteins & peptides market, with sustained momentum expected beyond 2030..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Asia Pacific oral proteins & peptides market valued at $514.2M in 2025, expanding to $1,135.0M by 2030 at 17.2% CAGR
    • Asia Pacific's large patient population and improving healthcare infrastructure drive demand for advanced oral peptide therapeutics
    • Asia Pacific manufacturers leverage cost advantages and regulatory pathways to accelerate product development and commercialization
    • Asia Pacific represents a high-growth opportunity for biopharmaceutical companies investing in oral bioavailability and peptide delivery innovation

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    Asia Pacific Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    Target Audience

    • Pharmaceutical & Biotech Companies : Manufacturers and developers of oral protein and peptide therapeutics require Asia Pacific market intelligence to guide R&D investments, clinical trial planning, regulatory submissions, and commercial launch strategies in high-growth markets.
    • Healthcare Investment Firms : Private equity, venture capital, and strategic investors need comprehensive Asia Pacific market data to evaluate investment opportunities, assess portfolio company growth potential, and identify acquisition targets in the oral biopharmaceutical sector.
    • Medical Device & Delivery Technology Providers : Companies developing oral delivery systems, formulation technologies, and enabling platforms require Asia Pacific market insights to understand demand drivers, competitive positioning, and partnership opportunities with pharmaceutical manufacturers.
    • Healthcare Consultants & Strategy Firms : Management consultants advising pharmaceutical and healthcare clients need Asia Pacific market analysis to support strategic planning, market entry assessments, competitive benchmarking, and growth opportunity identification for clients.
    • Regulatory & Market Access Professionals : Regulatory affairs specialists and market access teams require region-specific data on Asia Pacific regulatory pathways, reimbursement trends, and market dynamics to navigate approvals and optimize commercial strategies across multiple countries.

    Key Companies in the Asia Pacific Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Asia Pacific vs. other regions

    HowAsia Pacific compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 5880.7 Million · 24.1% wtd CAGR ·
    Europe
    ~USD 3180.3 Million · 21% wtd CAGR ·
    Latin America
    ~USD 650.7 Million · 13.9% wtd CAGR ·

    Countries within Asia Pacific - compare and drill down

    Country2025 size (native)
    ChinaUSD 219.7 Million
    JapanUSD 300.7 Million
    IndiaUSD 297.4 Million
    AustraliaUSD 148 Million
    South KoreaUSD 135 Million
    Rest Of Asia PacificUSD 34.3 Million

    Country market size visualization

    China
    USD 219.7 Million
    Japan
    USD 300.7 Million
    India
    USD 297.4 Million
    Australia
    USD 148 Million
    South Korea
    USD 135 Million
    Rest Of Asia Pacific
    USD 34.3 Million

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuations for Asia Pacific ($514.2M in 2025) with detailed 5-year forecasts through 2030, enabling accurate budgeting and strategic planning for market entry or expansion initiatives across the region.
    • Country-Level Intelligence : Access granular market data for key Asia Pacific economies including China, Japan, India, South Korea, and Australia, allowing targeted investment decisions and localized go-to-market strategies for oral protein and peptide products.
    • Competitive Landscape Analysis : Understand market dynamics, competitive positioning, and emerging players specific to Asia Pacific, identifying partnership opportunities, acquisition targets, and white-space opportunities in this high-growth region.
    • Growth Driver Identification : Gain insights into region-specific factors driving 17.2% CAGR growth, including chronic disease prevalence, regulatory trends, healthcare spending patterns, and technological adoption rates unique to Asia Pacific markets.
    • Risk Mitigation & Opportunity Assessment : Evaluate market maturity, regulatory environments, and reimbursement landscapes across Asia Pacific countries to identify high-potential markets, assess entry barriers, and develop risk-informed commercialization strategies.

    Frequently asked questions

    What is the current market size of oral proteins & peptides in Asia Pacific?

    Asia Pacific's oral proteins & peptides market was valued at $514.2 million in 2025 and is projected to grow to $1,135.0 million by 2030.

    What is the expected growth rate for Asia Pacific oral proteins & peptides market?

    Asia Pacific's oral proteins & peptides market is expected to grow at a compound annual growth rate (CAGR) of 17.2% from 2025 to 2030.

    What factors are driving growth in Asia Pacific's oral proteins & peptides market?

    Key drivers include rising chronic disease prevalence, expanding biopharmaceutical R&D investments, improving healthcare infrastructure, and advances in oral bioavailability technologies across Asia Pacific.

    Which countries in Asia Pacific are leading the oral proteins & peptides market?

    Major markets within Asia Pacific include China, Japan, India, and South Korea, which have strong pharmaceutical manufacturing bases and growing healthcare spending.

    What are the main challenges for the Asia Pacific oral proteins & peptides market?

    Challenges include regulatory complexity across different Asia Pacific countries, manufacturing scale-up costs, and competition from established global players entering the region.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status